Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by O'Riordan, E.
Right arrow Articles by Foley, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O'Riordan, E.
Right arrow Articles by Foley, R. N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2001) 16: 891-892
© 2001 European Renal Association-European Dialysis and Transplant Association

Editorial Comments

When should we start erythropoietin therapy?

Edmond O'Riordan and Robert N. Foley

Department of Nephrology, Salford Royal Hospitals NHS Trust, Hope Hospital, Salford, UK

Keywords: anaemia; cardiac enlargement; cardiac failure; erythropoietin; haemodialysis; renal function

Introduction

Evidence has accumulated over the last decade linking anaemia with cardiac enlargement, cardiac failure, and death, in the haemodialysis population. Observational studies have suggested that these features may be part of a pathological cascade that frequently occurs with declining renal function. The starting point for this cascade, anaemia, begins well before the onset of end-stage renal disease in most patients. Typically, this process begins as glomerular filtration falls below 30 ml/min [1]. Despite the routine availability of recombinant human erythropoietin, our approach to renal anaemia has been one of delayed intervention and variable haemoglobin targets, which are, in general, below population levels.

Evidence from observational studies

Several recent studies with . . . [Full Text of this Article]

Target haemoglobin levels: recent controlled trials

Conclusion

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?